Your browser doesn't support javascript.
loading
Generalized myasthenia gravis patients infected with COVID-19 should continue eculizumab.
Mimori, Masahiro; Komatsu, Teppei; Maku, Takahiro; Mitsumura, Hidetaka; Iguchi, Yasuyuki.
Afiliação
  • Mimori M; Department of Neurology, The Jikei University School of Medicine, Tokyo, Japan. mr.gaspard.de.la.nuit@gmail.com.
  • Komatsu T; Department of Neurology, The Jikei University School of Medicine, Tokyo, Japan.
  • Maku T; Department of Neurology, The Jikei University School of Medicine, Tokyo, Japan.
  • Mitsumura H; Department of Neurology, The Jikei University School of Medicine, Tokyo, Japan.
  • Iguchi Y; Department of Neurology, The Jikei University School of Medicine, Tokyo, Japan.
Neurol Sci ; 43(7): 4081-4083, 2022 Jul.
Article em En | MEDLINE | ID: mdl-35364770
ABSTRACT
Eculizumab, a humanized monoclonal antibody, is a complement inhibitor indicated for refractory generalized myasthenia gravis (MG). However, there are limited data on the safety of eculizumab for MG during coronavirus disease 2019 (COVID-19) infection. We report a case in which eculizumab was continued for MG after contracting COVID-19, followed by a favorable outcome.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 / Miastenia Gravis Limite: Humans Idioma: En Revista: Neurol Sci Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: COVID-19 / Miastenia Gravis Limite: Humans Idioma: En Revista: Neurol Sci Ano de publicação: 2022 Tipo de documento: Article